{"id":10781,"date":"2024-11-01T16:58:47","date_gmt":"2024-11-01T08:58:47","guid":{"rendered":"https:\/\/flcube.com\/?p=10781"},"modified":"2024-11-03T21:23:40","modified_gmt":"2024-11-03T13:23:40","slug":"national-reimbursement-drug-list-nrdl-negotiations-conclude-with-lower-generic-drug-approval-rate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10781","title":{"rendered":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate"},"content":{"rendered":"\n

The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from outside the NRDL and 45 within it.<\/p>\n\n\n\n

A total of 445 drugs passed the formality review in this negotiation round, with several innovative drugs being involved in the negotiation for the first time. Notable among them were Akeso Biopharma\u2019s (HKG: 9926<\/a>) PD-1\/CTLA-4 targeted bispecific antibody (BsAb) cadonilimab and PD-1\/VEGF-targeted BsAb ivonescimab, Dizal Pharmaceutical Co., Ltd\u2019s (SHA: 688192<\/a>) EGFR inhibitor sunvozertinib and JAK1 inhibitor golidocitinib, Jingxin Pharmaceutical Co., Ltd\u2019s (SHE: 002020<\/a>) GABAA regulator Didaxini, and Innovent Biologics Inc.\u2019s (HKG: 1801<\/a>) tafolecimab, an anti-PCSK-9 monoclonal antibody (mAb).<\/p>\n\n\n\n

Multinational pharmaceutical companies also had significant drugs in the spotlight, including AstraZeneca \/Daiichi Sankyo\u2019s TROP2-targeted antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-Dxd), Novartis\u2019 siRNA therapy Leqvio (inclisiran), BMS\u2019 TYK2 inhibitor Sotyktu (deucravacitinib), and Roche\u2019s ophthalmology BsAb Vabysmo (faricimab).- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than…<\/p>\n","protected":false},"author":1,"featured_media":10782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[360,92,191,910,850,198,1826,101,981,1827],"class_list":["post-10781","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-akeso-biopharma","tag-bmi","tag-dizal-pharmaceutical","tag-hkg-1801","tag-hkg-9926","tag-innovent-biologics","tag-jingxin-pharmaceutical","tag-nationally-negotiated-drugs","tag-sha-688192","tag-she-002020"],"yoast_head":"\nNational Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from outside the NRDL and 45 within it.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10781\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10781\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-01T08:58:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-03T13:23:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate\",\"datePublished\":\"2024-11-01T08:58:47+00:00\",\"dateModified\":\"2024-11-03T13:23:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781\"},\"wordCount\":185,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/98af1c21647adcc955dfe9e79f191bc7.jpg\",\"keywords\":[\"Akeso Biopharma\",\"BMI\",\"Dizal Pharmaceutical\",\"HKG: 1801\",\"HKG: 9926\",\"Innovent Biologics\",\"Jingxin Pharmaceutical\",\"Nationally negotiated drugs\",\"SHA: 688192\",\"SHE: 002020\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10781#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10781\",\"name\":\"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/98af1c21647adcc955dfe9e79f191bc7.jpg\",\"datePublished\":\"2024-11-01T08:58:47+00:00\",\"dateModified\":\"2024-11-03T13:23:40+00:00\",\"description\":\"The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from outside the NRDL and 45 within it.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10781\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/98af1c21647adcc955dfe9e79f191bc7.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/98af1c21647adcc955dfe9e79f191bc7.jpg\",\"width\":1280,\"height\":720,\"caption\":\"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10781#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate - Insight, China's Pharmaceutical Industry","description":"The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from outside the NRDL and 45 within it.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10781","og_locale":"en_US","og_type":"article","og_title":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10781","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-01T08:58:47+00:00","article_modified_time":"2024-11-03T13:23:40+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10781#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10781"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate","datePublished":"2024-11-01T08:58:47+00:00","dateModified":"2024-11-03T13:23:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10781"},"wordCount":185,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=10781#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg","keywords":["Akeso Biopharma","BMI","Dizal Pharmaceutical","HKG: 1801","HKG: 9926","Innovent Biologics","Jingxin Pharmaceutical","Nationally negotiated drugs","SHA: 688192","SHE: 002020"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10781#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10781","url":"https:\/\/flcube.com\/?p=10781","name":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=10781#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=10781#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg","datePublished":"2024-11-01T08:58:47+00:00","dateModified":"2024-11-03T13:23:40+00:00","description":"The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than 50% of the total 162 participating generic name drugs passing the expert review. This approval rate is a decrease compared to 74.2% in 2022 and 63.8% in 2023. The successful drugs included 117 varieties from outside the NRDL and 45 within it.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10781#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10781"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=10781#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg","width":1280,"height":720,"caption":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10781#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/98af1c21647adcc955dfe9e79f191bc7.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10781"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10781\/revisions"}],"predecessor-version":[{"id":10783,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10781\/revisions\/10783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/10782"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}